ããã¯ãã¼ã¯ãã¾ãã ããã«ãã¤ã¼ãå 容ãè¨è¼ããã¾ã https://b.hatena.ne.jp/URLã¯spanã§å²ãã§ãã ãã Twitterã§å ±æ

å¼ç¤¾ã®ã¹ã¿ããåãã«æ¨å¥¨ãã¦ããæç§æ¸ãªã¹ãããç´¹ä»ãæ°åãä¸éå ¥ç¤¾ã«ãããããå ¨ç¤¾å¡ã対象ã§ãã ãã®æç§æ¸ãªã¹ãã«ããæ¬ã¯ããã®1åã§äººçãå¤ãã£ãï¼ãã¨ãããé¡ã®ãã®ã§ã¯ãªãå ¥éæ¸çãªãã®ã§ãã¨ã³ã¸ãã¢ï¼å¶æ¥ï¼ãã¼ã±ãã£ã³ã°ï¼CSçã®è·ç¨®ã«ããããããå ¨ã¦ã®äººã«æä½éç解ãã¦èº«ã«ã¤ãã¦æ¬²ããå 容ã§ãã å¦æ ¡ãèªæ¸ãããæ確ãªåé¡æèããã£ã¦æ¥ã ã®ä»äºã«çæ¯ã«åãçµããã¨ããã¸ãã¹ãã¼ã½ã³ã¨ãã¦ã®å¤§ããªæé·ã«ã¤ãªããã¨ä¿¡ãã¦ãã¾ããã§ããä»äºã ãã§ã¯æé·ã§ãã¾ãããã¤ãã³ããSNSã§åºæ¿ãåããã®ã大åã ãã©ãåºç¤ããªãã¨ããããå½¹ã«ç«ããªãããåå¼·ãã¦ãªã人ã®åºã®æµ ãã¯ãããã¬ã¦ãã¾ãã åºç¤è½åã伸ã°ãã«ã¯ä½ç³»ã ã£ãç¥èã¨ç解ãå¿ è¦ã§ãå ¥éæ¸ãèªããã¨ãä¸çªã®è¿éãããããåå°ãå¼ãä¸ããåªåããå¼ç¤¾ãæä¾ãããç¾å ´åãåç»æè²ã·ã¹ãã tebikiãã®äºæ¥éçºã«ãå½¹ç«ã£ã¦ãããªã¼
æãããçããªããããã§ããããã©ã»ãããã§ããçãã£ã¦ããã®ãã«ãï¼å¤§æã®æ²ã§ææªæ®ºäººäºä»¶ã¦ãããã©æ¤åææªãããä»ã¨ãªã£ã¦ã¯ã»ãããã§ããªãã«ãã
縫製è·ããã¦ããè ã§ãã縫製ã¯èª°ã§ãåºæ¥ãä»äºã ã¨æã£ã¦ãããã§ããããï¼ç´ 人ã«ç¸«ãããå»çç¨ã¬ã¦ã³ã¨ããã®ç¸«è£½è·ã«ç¸«ãããå»çç¨ã¬ã¦ã³ãã¯ãªãªãã£å·®ã¯æ´ç¶ãã¨â¦ä»ã¯ç¸«è£½ã®ç¾å ´ãã³ããã®å½±é¿ã§ä»äºãæ¸ã人å¡ãä½ã£ã¦ãã¾ããã¾ãã¯ã⦠https://t.co/fCQiiZhbOY
æ°åã³ããã¦ã¤ã«ã¹ã®ã¯ã©ã¹ã¿ã¼ï¼ææéå£ï¼ãçºçããå½ç«ç é¢æ©æ§å¤§åå»çã»ã³ã¿ã¼ï¼å¤§åå¸ï¼ã¯ï¼æ¥ãå¤æ¥è¨ºçã®ä¸é¨ãåéãããåçå´åçã¯ã©ã¹ã¿ã¼å¯¾ççã¯ãè·å¡ããå ±ç¨ããã¿ãã¬ãã端æ«ãä¼æ©å®¤ã§ææãåºãã£ãå¯è½æ§ãææãé¢å ææ対çãªã©æ§ã ãªèª²é¡ãæµ®ã彫ãã«ãªã£ãã大è¦æ¨¡ãªéå£ææã¯å»çå´©å£ãå¼ãèµ·ãããããã大åçã¯å»çæ©é¢ãé«é½¢è ç¦ç¥æ½è¨ã«å¯¾çã®å¾¹åºãå¼ã³ããã¦ãããï¼é¢å±æ´å¹³ãé·è°·é¨ä½³åï¼ ãåçç¹éãç·æ¥äºæ 宣è¨â¦å¤ããæ¥å¸¸ãã¾ã°ããªäººéã ãæããããã¢ããã®æ¶æ¯ã¯å¾¹åºãã¦ããããã¿ãã¬ãã端æ«ã¯ãã£ã¦ããªãã£ããã¾ãããããããææãåºããã¨ã¯â¦â¦ããã»ã³ã¿ã¼ã®é¢ä¿è ã¯ã対ççã®ææãç²ç¹ã ã£ããã¨ãæãããã ï¼æï¼ï¼æ¥ã«å å ¥é¢æ£è ã®ç·æ§ã®ææã確èªãããå»å¸«ãçè·å¸«ãæ£è ãã®é½æ§ã次ã ã¨å¤æãåå´çã¯ææçµè·¯ã®ç¹å®ãæ¡å¤§é²æ¢ã®ãããã¯ã©ã¹ã¿ã¼å¯¾ççãæ´¾é£ããã 対ççã¯å
æ°ã¥ãã¨åéã¯æããã¦ããã ã©ããã¦ãããªã£ããã ⦠ä»åã¯4/7ã®å¤ã«1é¨ã®Twitterã§èµ·ããã©ã³ãµã¼ãºäºä»¶ã«ããã¦åãåè¯ãªTwitterã¦ã¼ã¶ã¼ããããã®æ¿æ²»å°è±¡æä½ãããbotããããç®çã¨ããä¼æ¥ã®å·¥ä½å¡ã¨åéãããä¸æ¹çã«æããããã¨ãåãã¦ããã«å¯¾ã㦠ããªãã§ãããªãã¨ã«ãªã£ãã®ãã ã詳ãã解説ãã 身ã®æ½ç½ã証æãããã¨æãã¾ãã é¨åãæç³»åé ã«ç°¡åã«ã¾ã¨ãã¾ãã 4/7 1.Twitterã«ããã¦ãã¡ãã®æ稿ã観測ããã â»å½¼ã¯åã¨FFã§æ¬äººããæ²è¼ã®è¨±å¯ã¯å¾ã¦ã¾ã åæå»ãå®åæä¸é¦ç¸ã«ããæ°åã³ããã¦ã¤ã«ã¹ã«é¢ããç·æ¥äºæ 宣è¨ã®ä¼è¦ã 2. 1ã®ãã¤ã¼ããè¦ããã©ãã¯ã¼éããã®ãã¤ã¼ããã³ãã¹ã 3.æ°ååå¾ã5ch(æ§2ch)ã«ããã¦ãããã®ãã¤ã¼ããã¾ã¨ããã¹ã¯ã·ã§ããã©ã³ãµã¼ãºã«ããå°è±¡æä½ï¼ãã®è¶£æ¨ã§æ¸ãè¾¼ã¾ãã 4. 3ã®æ¸ãè¾¼ã¿ãçºè¦ããTwi
ãã¬ã¼ã·ã¢ã»ã¯ã¢ã©ã«ã³ãã¼ã«ã®åºå ã«ä¸¦ã¶ã³ã³ãã¼ã ï¼2020å¹´4æ6æ¥æ®å½±ï¼ã(c)Mohd RASFAN / AFP ã4æ8æ¥ AFPãæ°åã³ããã¦ã¤ã«ã¹æææ¡å¤§ã«ãã製é å·¥å ´ã®ééãæµéã®æ··ä¹±ã§ãä¸ççãªã³ã³ãã¼ã ä¸è¶³ãæ¸å¿µããã¦ããããã§ã«ä¸çæ大ã®ã³ã³ãã¼ã ã¡ã¼ã«ã¼ã§ãããã¬ã¼ã·ã¢ã®ãã«ã¬ãã¯ã¹ï¼Karexï¼ããçç£æ¸ã«è¿½ãè¾¼ã¾ãã¦ãããå½é£ï¼UNï¼ã¯ãç ´æ» çããªå½±é¿ãåã¼ããããªãã¨è¦éãé³´ããã¦ããã ãåç»ãæ°åã³ããã§ãã©ã¤ãã·ã¼ç²å¾ã10å¹´ã¬ã¹ã®ãã³ããã¤ãã«äº¤å°¾ é¦æ¸¯ ä¸çæ大ã®ã´ã ã®ç£å°ã§ãã³ã³ãã¼ã ã®ä¸»è¦çç£å½ã§ããããã¬ã¼ã·ã¢ã¯å æãæ°åã³ããã¦ã¤ã«ã¹ã®ææè æ°ãæ±åã¢ã¸ã¢ã§æå¤ã¯ã©ã¹ã¨ãªã£ããã¨ãåããå ¨å½è¦æ¨¡ã®ããã¯ãã¦ã³ï¼é½å¸å°éï¼ã«è¸ã¿åã£ãã ä¸çã§è²©å£²ãããã³ã³ãã¼ã ã®5åã®1ãçç£ããã«ã¬ãã¯ã¹ãçç£æ´»åãå¶éããã3æä¸æ¬ãã4æä¸æ¬ã¾ã§ã®çç£æ°
æ°åã³ããã¦ã¤ã«ã¹ï¼COVID-19ï¼å¯¾çã¨ãã¦ãä»äººã¨ã®æ¥è§¦ã8å²åæ¸ãããç®æ¨ãç·æ¥äºæ 宣è¨ã§æã¡åºããã4æ8æ¥ããæ±äº¬é½ãªã©7é½åºçã§å¤åºèªç²æªç½®ãå§ã¾ãã¾ãããè±å½ã¯ãã欧米åå½ã®æ¿çã¨çãã¯åãã§ãæ£è ã®ççºçå¢å ãé£ãæ¢ããé ¼ã¿ã®ç¶±ã¨èãããã¦ãã¾ããä¸ã§ãè±å½ã¯å½åãCOVID-19 ã«å¯¾ãã¦ãç¹æ®µã®ä»å ¥ãè¡ããã«ãéå£å ç«ã®ç²å¾ãå¾ ã¤ãã¨ããæ¶æ¥µçãªå§¿å¢ãã¨ã£ã¦ãã¾ããï¼2020/3/5 [FT]è±ã®æ°åã³ãã対çããæåé¡ãææªã«åãããï¼ããããã3æ16æ¥ã«å½å ç 究æ©é¢ã® Imperial College London ãå ¬è¡¨ããè«æï¼Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demandï¼ããä½ãä»å ¥
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}